Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of EML4-ALK Lung Cancer

被引：0
|
作者：
Arai, S. [1 ]
Takeuchi, S. [1 ]
Fukuda, K. [1 ]
Nishiyama, A. [1 ]
Tanimoto, A. [1 ]
Taniguchi, H. [1 ]
Satouchi, M. [2 ]
Nanjo, S. [1 ]
Katayama, R. [3 ]
Nishio, M. [4 ]
Zheng, M. [5 ]
Wu, Y. [6 ,7 ]
Yano, S. [1 ]
机构：
[1] Kanazawa Univ, Canc Res Inst, Kanazawa, Ishikawa, Japan
[2] Hyogo Canc Ctr, Akashi, Hyogo, Japan
[3] Japanese Fdn Canc Res, Canc Chemotherapy Ctr, Tokyo, Japan
[4] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[5] Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[6] Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[7] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
leptomeningeal carcinomatosis; alectinib resistance; Osimertinib;
D O I：
10.1016/j.jtho.2019.08.1841
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.14-56
引用
收藏
页码：S852 / S853
页数：2
相关论文
共 50 条
  • [41] Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib
    Pop, Oana
    Pirvu, Augustin
    Toffart, Anne-Claire
    Moro-Sibilot, Denis
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (08) : E1 - E2
  • [42] Clinical Outcomes and ALK Resistance Mutations in ALK plus Non-Small Cell Lung Cancer According to EML4-ALK Variant
    Lin, J.
    Zhu, V.
    Yoda, S.
    Yeap, B.
    Jessop, N.
    Schrock, A.
    Dagogo-Jack, I.
    Gowen, K.
    Stephens, P. J.
    Ross, J.
    Ali, S.
    Miller, V.
    Gainor, J.
    Hata, A.
    Iafrate, A.
    Ou, S.
    Shaw, A.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1828 - S1828
  • [43] The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement
    Bilgin, Burak
    Sendur, Mehmet Ali Nahit
    Yucel, Sebnem
    Hizal, Mutlu
    Guner, Gurkan
    Akyurek, Nalan
    Erol, Cihan
    Akinci, Muhammed Bulent
    Dede, Didem Sener
    Yalcin, Bulent
    Kilickap, Sadettin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (09) : 2637 - 2643
  • [44] The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement
    Burak Bilgin
    Mehmet Ali Nahit Şendur
    Şebnem Yücel
    Mutlu Hizal
    Gürkan Güner
    Nalan Akyürek
    Cihan Erol
    Muhammed Bülent Akıncı
    Didem Şener Dede
    Bülent Yalçın
    Sadettin Kılıçkap
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 2637 - 2643
  • [45] MONO INSTITUTIONAL EXPERIENCE IN NON SMALL LUNG CANCER WITH EML4-ALK REARRANGEMENT
    Perez Mesa, Pablo Jose
    Guadalupe Pallotta, Maria
    De La Iglesia, Paola
    Lupinacci, Lorena
    Liliana Dalurzo, Mercedes
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S170 - S170
  • [46] CLINICOPATHOLOGICAL INCIDENCE, SIGNIFICANCE, AND SURVIVAL OUTCOMES OF EML4-ALK TRANSLOCATION IN LUNG CANCER
    Guggisberg, Natalia V.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : S128 - S128
  • [47] The Role of Immunohistochemical Analysis in the Evaluation of EML4-ALK Rearrangement Status in Lung Cancer
    Sullivan, H. C.
    Siddiqui, M. T.
    Wang, J.
    Cohen, C.
    LABORATORY INVESTIGATION, 2013, 93 : 468A - 468A
  • [48] CCN1 is a therapeutic target upregulated in EML4-ALK mutant lung adenocarcinoma reversibly resistant to alectinib
    Yihua Huang
    Jie Huang
    Jianhua Zhan
    Maojian Chen
    Jiani Zheng
    Junyi He
    Wenfeng Fang
    Li Zhang
    Jing Li
    Cell Death & Disease, 16 (1)
  • [49] The biology and treatment of EML4-ALK non-small cell lung cancer
    Sasaki, Takaaki
    Rodig, Scott J.
    Chirieac, Lucian R.
    Janne, Pasi A.
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (10) : 1773 - 1780
  • [50] EML4-ALK fusion gene in non-small cell lung cancer
    Lei, Yu
    Lei, Yan
    Shi, Xiang
    Wang, Jingjing
    ONCOLOGY LETTERS, 2022, 24 (02)
12345